MetLife Investment Management LLC Acquires Shares of 30,613 Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

MetLife Investment Management LLC acquired a new stake in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,613 shares of the company’s stock, valued at approximately $87,000.

Several other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Nautilus Biotechnology by 1.0% during the first quarter. Vanguard Group Inc. now owns 2,859,402 shares of the company’s stock valued at $8,407,000 after purchasing an additional 29,604 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Nautilus Biotechnology by 19.8% during the second quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock valued at $1,345,000 after purchasing an additional 94,908 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Nautilus Biotechnology by 11.2% during the second quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock valued at $328,000 after purchasing an additional 14,100 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Nautilus Biotechnology by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock valued at $69,000 after purchasing an additional 9,404 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in Nautilus Biotechnology during the third quarter valued at about $67,000. 50.71% of the stock is owned by hedge funds and other institutional investors.

Nautilus Biotechnology Stock Down 2.8 %

Shares of NAUT opened at $2.11 on Wednesday. The business’s 50-day moving average price is $2.54 and its 200-day moving average price is $2.56. Nautilus Biotechnology, Inc. has a twelve month low of $1.88 and a twelve month high of $3.45. The stock has a market cap of $264.94 million, a PE ratio of -3.77 and a beta of 1.14.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.04. During the same period in the prior year, the firm earned ($0.13) EPS. Analysts expect that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group downgraded shares of Nautilus Biotechnology from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $2.25 to $1.75 in a report on Thursday, December 5th.

Insider Activity

In related news, VP Mary E. Godwin sold 47,031 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $2.87, for a total value of $134,978.97. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 40.50% of the company’s stock.

Nautilus Biotechnology Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.